Molecular testing to determine BRAF mutation status has therefore become standard-of-care in the modern clinical management of patients with advanced MM, being currently the only available biomarker that can predict therapeutic responses to treatments with combined BRAF and MEK inhibitors. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.